{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:42:05Z","timestamp":1769838125862,"version":"3.49.0"},"reference-count":96,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy of several drugs has been evaluated and variability in drug response has been observed. Pharmacogenetics could explain this variation and improve patients\u2019 outcomes with this complex disease; nevertheless, several disease-related issues must be carefully reviewed in the pharmacogenetic study of COVID-19 treatment. We aimed to describe the pharmacogenetic variants reported for drugs used for COVID-19 treatment (remdesivir, oseltamivir, lopinavir, ritonavir, azithromycin, chloroquine, hydroxychloroquine, ivermectin, and dexamethasone). In addition, other factors relevant to the design of pharmacogenetic studies were mentioned. Variants in CYP3A4, CYP3A5, CYP2C8, CY2D6, ABCB1, ABCC2, and SLCO1B1, among other variants, could be included in pharmacogenetic studies of COVID-19 treatment. Besides, nongenetic factors such as drug\u2013drug interactions and inflammation should be considered in the search for personalized therapy of COVID-19.<\/jats:p>","DOI":"10.3390\/v13030413","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T05:03:15Z","timestamp":1614920595000},"page":"413","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacogenetics Approach for the Improvement of COVID-19 Treatment"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-1076","authenticated-orcid":false,"given":"Ingrid","family":"Fricke-Galindo","sequence":"first","affiliation":[{"name":"HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Mexico City 14080, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6877-8124","authenticated-orcid":false,"given":"Ramc\u00e9s","family":"Falf\u00e1n-Valencia","sequence":"additional","affiliation":[{"name":"HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Mexico City 14080, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bja.2020.06.013","article-title":"COVID-19: A complex multisystem disorder","volume":"125","author":"Roberts","year":"2020","journal-title":"Br. J. Anaesth."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jmv.26294","article-title":"Extrapulmonary complications of COVID-19: A multisystem disease?","volume":"93","author":"Zheng","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"604339","DOI":"10.3389\/fpubh.2020.604339","article-title":"Covid-19 mortality: A matter of vulnerability among nations facing limited margins of adaptation","volume":"8","author":"Marc","year":"2020","journal-title":"Front. Public Health"},{"key":"ref_4","unstructured":"(2020, December 19). COVID-19 Treatment Guidelines, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1093\/jac\/dkaa195","article-title":"Lopinavir pharmacokinetics in COVID-19 patients","volume":"75","author":"Gregoire","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/B978-0-444-63233-3.00006-3","article-title":"Pharmacogenetics","volume":"Volume 147","author":"Bishop","year":"2018","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_7","first-page":"35","article-title":"Pharmacogenomics of COVID-19 therapies","volume":"5","author":"Takahashi","year":"2020","journal-title":"Genom. Med."},{"key":"ref_8","first-page":"531","article-title":"Repurposing drugs for COVID-19: Pharmacokinetics and pharmacogenomics of chloroquine and hydroxychloroquine","volume":"13","author":"Babayeva","year":"2020","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/cts.12866","article-title":"Important pharmacogenetic information for drugs prescribed during the SARS-CoV-2 infection (COVID-19)","volume":"13","author":"Zubiaur","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and Synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"Feldmann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1136\/bmj.m2924","article-title":"Rapid recommendations Remdesivir for severe covid-19: A clinical practice guideline","volume":"370","author":"Rochwerg","year":"2020","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wilt, T.J., Kaka, A.S., MacDonald, R., Greer, N., Obley, A., and Duan-Porter, W. (2020). Remdesivir for adults with COVID-19. Annu. Intern. Med.","DOI":"10.7326\/M20-5752"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1093\/jac\/dkaa239","article-title":"Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19","volume":"75","author":"Tempestilli","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","unstructured":"European Medicines Agency (2021, February 19). Remdesivir Gilead, INN-Remdesivir. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/veklury-product-information-approved-chmp-25-june-2020-pending-endorsement-european-commission_en.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3109\/09540261.2013.825581","article-title":"Complexities of CYP2D6 gene analysis and interpretation","volume":"25","author":"Gaedigk","year":"2013","journal-title":"Int. Rev. Psychiatr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/17425255.2014.964204","article-title":"Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations","volume":"10","author":"LLerena","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardizing CYP2D6 genotype to phenotype translation: Consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.02-0195fje","article-title":"Down-regulation of human CYP3A4 by the inflammatory signal interleukin 6: Molecular mechanism and transcription factors involved","volume":"16","author":"Jover","year":"2002","journal-title":"FASEB J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/phar.2429","article-title":"Remdesivir: Review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1124\/dmd.115.069252","article-title":"Expression patterns of organic anion transporting polypeptides 1B1 and 1B3 protein in human pediatric liver","volume":"44","author":"Thomson","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2133\/dmpk.DMPK-12-RV-099","article-title":"Impact of genetic variation in OATP transporters to drug disposition and response","volume":"28","author":"Gong","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Muderrisoglu, A., Babaoglu, E., Korkmaz, E.T., Ongun, M.C., Karabulut, E., Iskit, A.B., Emri, S., and Babaoglu, M.O. (2020). Effects of genetic polymorphisms of drug transporter ABCB1 (MDR1) and cytochrome P450 enzymes CYP2A6, CYP2B6 on nicotine addiction and smoking cessation. Front. Genet., 11.","DOI":"10.3389\/fgene.2020.571997"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1128\/AAC.47.1.350-359.2003","article-title":"Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients","volume":"47","author":"Hsu","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","article-title":"Lopinavir\/ritonavir: A review of its use in the management of HIV infection","volume":"63","author":"Cvetkovic","year":"2003","journal-title":"Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2125.2005.02455.x","article-title":"Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients","volume":"60","author":"Crommentuyn","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200241040-00001","article-title":"The mucosa of the small intestine: How clinically relevant as an organ of drug metabolism?","volume":"41","author":"Doherty","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/FPC.0b013e328335b02d","article-title":"HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms","volume":"20","author":"Hartkoorn","year":"2010","journal-title":"Pharmacogenet. Genom."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3851\/IMP2095","article-title":"Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults","volume":"17","author":"Schipani","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FPC.0000000000000073","article-title":"CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults","volume":"24","author":"Olagunju","year":"2014","journal-title":"Pharmacogenet. Genom."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/pgs.16.14","article-title":"Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans","volume":"17","author":"Mpeta","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/FTD.0b013e318225384f","article-title":"CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir\/ritonavir in HIV-infected children","volume":"33","author":"Rakhmanina","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/14622416.10.2.311","article-title":"ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy","volume":"10","author":"Ribeiro","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref_38","first-page":"4201","article-title":"Mutation analysis of the ABCC2 gene in Chinese patients with Dubin-Johnson syndrome","volume":"16","author":"Wu","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/FPC.0b013e3283528217","article-title":"Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on first-line antiepileptic drugs","volume":"22","author":"Grover","year":"2012","journal-title":"Pharmacogenet. Genom."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2217\/pgs.09.88","article-title":"Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients","volume":"10","author":"Elens","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/FPC.0000000000000169","article-title":"Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort","volume":"25","author":"Gasparotto","year":"2015","journal-title":"Pharmacogenet. Genom."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FPC.0b013e328351d47f","article-title":"PharmGKB summary: Very important pharmacogene information for CYP3A5","volume":"22","author":"Lamba","year":"2012","journal-title":"Pharmacogenet. Genom."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1124\/jpet.106.111807","article-title":"Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel","volume":"319","author":"Shi","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Chiba, S. (2020). Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19. Wien. Klin. Wochenschr., 1\u20136.","DOI":"10.21203\/rs.3.rs-33046\/v1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"104257","DOI":"10.1016\/j.bioorg.2020.104257","article-title":"Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study","volume":"104","author":"Tan","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","article-title":"Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802","volume":"37","author":"He","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1124\/dmd.107.017699","article-title":"Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein","volume":"36","author":"Morimoto","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Jefferson, T., Jones, M., Doshi, P., Spencer, E.A., Onakpoya, I., and Heneghan, C.J. (2014). Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ, 348.","DOI":"10.1136\/bmj.g2545"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/clpt.2012.13","article-title":"Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans","volume":"92","author":"Tarkiainen","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Oh, J., Lee, S., Lee, H., Cho, J.Y., Yoon, S.H., Jang, I.J., Yu, K.S., and Lim, K.S. (2017). The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176320"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41397-020-0151-8","article-title":"Association study of genetic polymorphisms in proteins involved in oseltamivir transport, metabolism, and interactions with adverse reactions in Mexican patients with acute respiratory diseases","volume":"20","year":"2020","journal-title":"Pharmacogen. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/j.1875-9114.1992.tb04504.x","article-title":"Azithromycin\u2014Spectrum of activity, pharmacokinetics, and clinical applications","volume":"12","author":"Drew","year":"1992","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Stocco, G., Lucaf\u00f2, M., and Decorti, G. (2020). Pharmacogenomics of antibiotics. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21175975"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Scherrmann, J. (2020). Possible role of ABCB1 in lysosomal accumulation of azithromycin in COVID-19 therapy. Clin. Pharmacol. Ther.","DOI":"10.1002\/cpt.2020"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-020-00465-w","article-title":"Intracellular ABCB1 as a possible mechanism to explain the synergistic effect of hydroxychloroquine-azithromycin combination in COVID-19 therapy","volume":"22","author":"Scherrmann","year":"2020","journal-title":"AAPS J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1734-1140(09)70140-9","article-title":"Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects","volume":"61","author":"He","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1139\/cjpp-2019-0569","article-title":"The effect of gender and abcb1 gene polymorphism on the pharmacokinetics of azithromycin in healthy male and female pakistani subjects","volume":"98","author":"Nazir","year":"2020","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1124\/dmd.31.6.748","article-title":"In vitro metabolism of chloroquine: Identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation","volume":"31","author":"Projean","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2217\/pgs-2016-0131","article-title":"The effect of SNPs in CYP450 in chloroquine\/primaquine Plasmodium vivax malaria treatment","volume":"17","author":"Sortica","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(09)70320-2","article-title":"Pharmacogenetics of antimalarial drugs: Effect on metabolism and transport","volume":"9","author":"Kerb","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2217\/pgs-2017-0077","article-title":"SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria","volume":"18","author":"Sortica","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.39402","article-title":"Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus","volume":"68","author":"Lee","year":"2016","journal-title":"Arthr. Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/pgs.13.198","article-title":"Pharmacogenomic biomarkers in drug labels: What do they tell us?","volume":"15","author":"Tutton","year":"2014","journal-title":"Pharmacogenomics"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/acr.23296","article-title":"Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-deficient patients","volume":"70","author":"Mohammad","year":"2018","journal-title":"Arthr. Care Res."},{"key":"ref_67","first-page":"001875","article-title":"Hydroxychloroquine in a G6PD-deficient patient with COVID-19 complicated by haemolytic anaemia: Culprit or innocent bystander?","volume":"7","author":"Mastroianni","year":"2020","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","article-title":"The pharmacokinetics and interactions of ivermectin in humans\u2014A mini-review","volume":"10","author":"Canga","year":"2008","journal-title":"AAPS J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/004982598239597","article-title":"Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes","volume":"28","author":"Zeng","year":"1998","journal-title":"Xenobiotica"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cbi.2005.11.002","article-title":"Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3)","volume":"159","author":"Lespine","year":"2006","journal-title":"Chem. Biol. Interact."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMc1917344","article-title":"Serious ivermectin toxicity and human ABCB1 nonsense mutations","volume":"383","author":"Baudou","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-9292-2-1","article-title":"Ivermectin: Does P-glycoprotein play a role in neurotoxicity?","volume":"2","author":"Edwards","year":"2003","journal-title":"Kinetoplastid Biol. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Telbisz, \u00c1., Ambrus, C., M\u00f3zner, O., Szab\u00f3, E., V\u00e1rady, G., Bakos, \u00c9., Sarkadi, B., and \u00d6zvegy-Laczka, C. (2020). Interactions of anti-COVID-19 drug candidates with multispecific ABC and OATP drug transporters. bioRxiv.","DOI":"10.1101\/2020.11.21.392555"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0960-0760(97)00038-1","article-title":"Dexamethasone metabolism in vitro: Species differences","volume":"62","author":"Tomlinson","year":"1997","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.taap.2012.03.008","article-title":"Oral and inhaled corticosteroids: Differences in P-glycoprotein (ABCB1) mediated efflux","volume":"260","author":"Crowe","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/hmg\/ddu191","article-title":"Pharmacogenomics: Novel loci identification via integrating gene differential analysis and eQTL analysis","volume":"23","author":"Qiu","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/dmd.107.016600","article-title":"Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor\/NR1I2 and their association with CYP3A4 expression","volume":"36","author":"Lamba","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/1389200054633880","article-title":"Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics","volume":"6","author":"Lamba","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2174\/1389200054633844","article-title":"Structure and function of the human nuclear xenobiotic receptor PXR","volume":"6","author":"Carnahan","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"ref_80","unstructured":"Oshiro, C. (2021, January 24). Very Important Pharmacogene: NR1I2. Available online: https:\/\/www.pharmgkb.org\/vip\/PA166170351."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions","volume":"102","author":"Lehmann","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3389\/fphar.2016.00456","article-title":"Pregnane X Receptor (PXR)-mediated gene repression and cross-talk of PXR with other nuclear receptors via coactivator interactions","volume":"7","author":"Pavek","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00008571-200110000-00003","article-title":"The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants","volume":"11","author":"Zhang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1177\/0091270006292125","article-title":"Human pregnane X receptor: Genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity","volume":"46","author":"He","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1158\/1078-0432.CCR-08-0411","article-title":"PXR pharmacogenetics: Association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients","volume":"14","author":"Sandanaraj","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.addr.2010.08.006","article-title":"Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR","volume":"62","author":"Tolson","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fimmu.2018.00089","article-title":"The role of cytochromes P450 in infection","volume":"9","author":"Stavropoulou","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Chakraborty, C., Sharma, A.R., Bhattacharya, M., Sharma, G., Lee, S., and Agoramoorthy, G. (2020). COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients. J. Med. Virol.","DOI":"10.1002\/jmv.26078"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Strafella, C., Caputo, V., Termine, A., Barati, S., Caltagirone, C., Giardina, E., and Cascella, R. (2020). Investigation of genetic variations of IL6 and IL6r as potential prognostic and pharmacogenetics biomarkers: Implications for covid-19 and neuroinflammatory disorders. Life, 10.","DOI":"10.21203\/rs.3.rs-77342\/v1"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1634\/theoncologist.2010-0258","article-title":"Part 1: Background, methodology, and clinical adoption of pharmacogenetics","volume":"16","author":"Deenen","year":"2011","journal-title":"Oncologist"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Mizzi, C., Dalabira, E., Kumuthini, J., Dzimiri, N., Balogh, I., Ba\u015fak, N., B\u00f6hm, R., Borg, J., Borgiani, P., and Bozina, N. (2016). A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162866"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/cge.13178","article-title":"A critical appraisal of pharmacogenetic inference","volume":"93","author":"Smit","year":"2018","journal-title":"Clin. Genet."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/2042098617712657","article-title":"Pharmacogenetics and precision medicine: Is inflammation a covert threat to effective genotype-based therapy?","volume":"8","author":"Shah","year":"2017","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2217\/pgs.13.70","article-title":"Role of interactions in pharmacogenetic studies: Leukotrienes in asthma","volume":"14","author":"Via","year":"2013","journal-title":"Pharmacogenomics"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/3\/413\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:33:14Z","timestamp":1760160794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/3\/413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":96,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["v13030413"],"URL":"https:\/\/doi.org\/10.3390\/v13030413","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]}}}